Cyanotech (CYAN) Receiving Somewhat Favorable Press Coverage, Report Finds
Media stories about Cyanotech (NASDAQ:CYAN) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cyanotech earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.3331722854112 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, TheStreet downgraded shares of Cyanotech from a “c” rating to a “d” rating in a research report on Monday, August 13th.
CYAN traded up $0.10 during trading on Friday, hitting $3.75. The company’s stock had a trading volume of 4,369 shares, compared to its average volume of 8,013. The company has a current ratio of 2.39, a quick ratio of 0.80 and a debt-to-equity ratio of 0.32. Cyanotech has a one year low of $3.45 and a one year high of $5.78. The company has a market capitalization of $21.29 million, a PE ratio of 20.43 and a beta of 0.64.
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company's products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Cyanotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyanotech and related companies with MarketBeat.com's FREE daily email newsletter.